Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ELVNNASDAQ:GYRENASDAQ:OCSNYSE:PLX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeELVNEnliven Therapeutics$21.16+4.3%$18.94$13.30▼$30.03$995.61M0.79293,740 shs645,327 shsGYREGyre Therapeutics$7.61-2.1%$9.13$6.11▼$19.00$728.50M1.79125,573 shs169,024 shsOCSOculis$19.75+0.5%$18.69$10.79▼$23.08$857.97M0.3545,318 shs32,078 shsPLXProtalix BioTherapeutics$1.53+13.3%$2.01$0.82▼$3.10$121.80M-0.2559,193 shs885,839 shs10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceELVNEnliven Therapeutics+4.29%-2.94%+29.02%+2.82%-3.11%GYREGyre Therapeutics-2.06%-5.93%-12.33%-13.42%-26.19%OCSOculis+0.51%+0.10%+3.89%+0.46%+66.53%PLXProtalix BioTherapeutics+13.33%+11.68%-5.56%-38.31%+20.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationELVNEnliven Therapeutics2.6581 of 5 stars3.51.00.00.03.04.20.0GYREGyre Therapeutics0.3399 of 5 stars0.03.00.00.01.80.80.0OCSOculis2.0893 of 5 stars3.53.00.00.01.90.00.6PLXProtalix BioTherapeutics2.711 of 5 stars3.54.00.00.00.60.01.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceELVNEnliven Therapeutics 3.00Buy$39.6087.15% UpsideGYREGyre Therapeutics 3.00BuyN/AN/AOCSOculis 3.00Buy$35.3378.90% UpsidePLXProtalix BioTherapeutics 3.00Buy$15.00880.39% UpsideCurrent Analyst Ratings BreakdownLatest PLX, ELVN, OCS, and GYRE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/16/2025ELVNEnliven TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$40.00 ➝ $52.006/16/2025ELVNEnliven TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$37.005/16/2025ELVNEnliven TherapeuticsJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$36.00 ➝ $27.005/15/2025ELVNEnliven TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$39.00 ➝ $40.005/9/2025OCSOculisChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$28.00 ➝ $33.004/17/2025OCSOculisHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$29.00 ➝ $32.004/17/2025OCSOculisChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.00 ➝ $28.00(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookELVNEnliven TherapeuticsN/AN/AN/AN/A$6.34 per shareN/AGYREGyre Therapeutics$105.76M6.75$0.19 per share39.34$1.05 per share7.25OCSOculis$780K1,105.49N/AN/A$1.91 per share10.34PLXProtalix BioTherapeutics$59.76M2.04$0.09 per share17.80$0.47 per share3.26Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateELVNEnliven Therapeutics-$89.02M-$1.92N/AN/AN/AN/A-31.84%-30.09%8/12/2025 (Estimated)GYREGyre Therapeutics$12.09M$0.02380.69∞N/A7.20%9.73%7.66%8/12/2025 (Estimated)OCSOculis-$97.43M-$2.64N/AN/AN/A-13,788.70%-92.95%-70.03%8/19/2025 (Estimated)PLXProtalix BioTherapeutics$8.31M$0.04N/A4.94N/A-21.03%-30.89%-11.74%N/ALatest PLX, ELVN, OCS, and GYRE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025ELVNEnliven Therapeutics-$0.51-$0.57-$0.06-$0.57N/AN/A5/9/2025Q1 2025GYREGyre Therapeutics$0.03$0.03N/AN/A$28.40 million$22.06 million5/9/2025Q1PLXProtalix BioTherapeuticsN/A-$0.05N/AN/AN/AN/A5/8/2025Q1 2025OCSOculis-$0.51-$0.77-$0.26-$0.77$0.22 million$0.32 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthELVNEnliven TherapeuticsN/AN/AN/AN/AN/AGYREGyre TherapeuticsN/AN/AN/AN/AN/AOCSOculisN/AN/AN/AN/AN/APLXProtalix BioTherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioELVNEnliven TherapeuticsN/A21.0721.06GYREGyre TherapeuticsN/A3.603.19OCSOculisN/A4.794.79PLXProtalix BioTherapeuticsN/A1.981.27Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipELVNEnliven Therapeutics95.08%GYREGyre Therapeutics23.99%OCSOculis22.30%PLXProtalix BioTherapeutics16.53%Insider OwnershipCompanyInsider OwnershipELVNEnliven Therapeutics25.90%GYREGyre Therapeutics10.00%OCSOculisN/APLXProtalix BioTherapeutics6.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableELVNEnliven Therapeutics5049.07 million36.36 millionOptionableGYREGyre Therapeutics4093.76 million84.38 millionNo DataOCSOculis243.66 millionN/ANot OptionablePLXProtalix BioTherapeutics20079.61 million69.00 millionOptionablePLX, ELVN, OCS, and GYRE HeadlinesRecent News About These CompaniesNorthern Trust Corp Has $1.38 Million Stock Position in Protalix BioTherapeutics, Inc. (NYSE:PLX)May 29, 2025 | marketbeat.comQ1 Earnings Estimate for PLX Issued By HC WainwrightMay 27, 2025 | marketbeat.comProtalix BioTherapeutics to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYCMay 14, 2025 | finance.yahoo.comPLX: First Quarter ResultsMay 13, 2025 | msn.comEarnings call transcript: Protalix Q1 2025 results miss forecasts, stock plungesMay 10, 2025 | uk.investing.comProtalix BioTherapeutics, Inc. (AMEX:PLX) Q1 2025 Earnings Call TranscriptMay 10, 2025 | insidermonkey.comProtalix BioTherapeutics, Inc.: Protalix BioTherapeutics Reports First Quarter 2025 Financial and Business ResultsMay 10, 2025 | finanznachrichten.deProtalix BioTherapeutics Q1 Earnings PreviewMay 10, 2025 | msn.com1PLX : Uncovering Potential: Protalix BioTherapeutics's Earnings PreviewMay 10, 2025 | benzinga.comProtalix BioTherapeutics, Inc. (PLX) Q1 2025 Earnings Call TranscriptMay 9, 2025 | seekingalpha.comProtalix eyes Phase II gout trial later this year following solid Q1 revenue growthMay 9, 2025 | proactiveinvestors.comProtalix BioTherapeutics Reports First Quarter 2025 Financial and Business ResultsMay 9, 2025 | prnewswire.comProtalix BioTherapeutics to Announce First Quarter 2025 Financial and Business Results on May 9, 2025May 6, 2025 | seekingalpha.comWhy Protalix BioTherapeutics, Inc.’s (PLX) Stock Is Up 8.71%April 15, 2025 | aaii.comProtalix BioTherapeutics Is A Strong Buy With Increasing Revenues And A Promising PipelineApril 10, 2025 | seekingalpha.comProtalix BioTherapeutics to Present at the iAccess Alpha Virtual Best Ideas Spring Conference 2025March 24, 2025 | finance.yahoo.comIs Protalix BioTherapeutics (PLX) The High Growth Low Debt Stock to Invest in Now?March 22, 2025 | msn.comProtalix Biotherapeutics chairman discusses breakthrough in gout treatment, drug pipeline - ICYMIMarch 21, 2025 | proactiveinvestors.comProtalix Stock (PLX) Grabbing Attention with Record Revenue SurgeMarch 20, 2025 | markets.businessinsider.comProtalix BioTherapeutics, Inc. (PLX) Q4 2024 Earnings Call TranscriptMarch 19, 2025 | seekingalpha.comEarnings call transcript: Protalix Q4 2024 sees 31% revenue growthMarch 19, 2025 | uk.investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePLX, ELVN, OCS, and GYRE Company DescriptionsEnliven Therapeutics NASDAQ:ELVN$21.16 +0.87 (+4.29%) Closing price 06/24/2025 04:00 PM EasternExtended Trading$21.15 -0.01 (-0.05%) As of 06/24/2025 04:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.Gyre Therapeutics NASDAQ:GYRE$7.61 -0.16 (-2.06%) Closing price 06/24/2025 04:00 PM EasternExtended Trading$7.62 +0.00 (+0.07%) As of 06/24/2025 05:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.Oculis NASDAQ:OCS$19.69 +0.04 (+0.20%) As of 06/24/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.Protalix BioTherapeutics NYSE:PLX$1.53 +0.18 (+13.33%) Closing price 06/24/2025 04:00 PM EasternExtended Trading$1.53 +0.00 (+0.07%) As of 04:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Hot Trades for Insiders, But Are They Good Buys for Investors? Why Qualcomm’s Latest Price Target Can't Be Ignored Texas Instruments Stock: Congress Likes It, Should You Too? Geospace Stock Skyrockets After Major Petrobras Contract Analyst Sees Meta Hitting $800: What May Lead Shares to New Highs CrowdStrike Eyes Breakout as Cyber Threats Boost Demand Reddit Stock Ignites: Surge in Call Options Signals Big Bet Microsoft Stock Holds Steady as AI Drives Workforce Shift Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
